Jeffrey Kooijman is an Investigator at Oncolines B.V., a Symeres company specializing in precision medicine services for oncology and cancer immunotherapy. Oncolines supports clinical and preclinical biopharma companies, as well as academic institutions worldwide, in differentiating their drugs and drug candidates through advanced cancer cell line profiling, mechanism-of-action studies, bioinformatics, and biochemical assays.

Jeffrey leads the Bioinformatics team at Oncolines. His work focuses on identifying predictive drug-response biomarkers and elucidating the mechanisms of action of anti-cancer compounds. He has developed several bioinformatic algorithms that integrate molecular and pharmacological data to support these analyses.

He holds a Master’s degree in Molecular Life Sciences and is currently pursuing a PhD at the Chemistry and Pharmaceutical Sciences department of the Vrije Universiteit Amsterdam.